Penserra Capital Management LLC Buys 12,603 Shares of Hologic, Inc. (NASDAQ:HOLX)

Penserra Capital Management LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2,069.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,212 shares of the medical equipment provider's stock after buying an additional 12,603 shares during the quarter. Penserra Capital Management LLC's holdings in Hologic were worth $815,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. IFM Investors Pty Ltd lifted its position in shares of Hologic by 12.0% during the 1st quarter. IFM Investors Pty Ltd now owns 56,081 shares of the medical equipment provider's stock worth $3,464,000 after buying an additional 5,996 shares during the period. OneDigital Investment Advisors LLC lifted its position in shares of Hologic by 7.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 7,247 shares of the medical equipment provider's stock worth $448,000 after buying an additional 528 shares during the period. Leeward Investments LLC MA lifted its position in shares of Hologic by 20.4% during the 1st quarter. Leeward Investments LLC MA now owns 166,615 shares of the medical equipment provider's stock worth $10,292,000 after buying an additional 28,240 shares during the period. Vontobel Holding Ltd. lifted its position in shares of Hologic by 34.8% during the 1st quarter. Vontobel Holding Ltd. now owns 39,475 shares of the medical equipment provider's stock worth $2,438,000 after buying an additional 10,185 shares during the period. Finally, KBC Group NV increased its holdings in Hologic by 4.1% during the 1st quarter. KBC Group NV now owns 97,233 shares of the medical equipment provider's stock valued at $6,006,000 after purchasing an additional 3,857 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Insider Activity

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is owned by corporate insiders.

Hologic Trading Down 1.7%

Shares of NASDAQ HOLX traded down $1.13 during midday trading on Friday, hitting $65.72. The stock had a trading volume of 1,776,763 shares, compared to its average volume of 2,391,464. The company's 50-day simple moving average is $61.55 and its 200 day simple moving average is $63.48. The firm has a market cap of $14.65 billion, a P/E ratio of 27.73, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company earned $1.03 EPS. The firm's revenue was down 1.2% on a year-over-year basis. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HOLX shares. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price target for the company from $60.00 to $80.00 in a report on Wednesday. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Finally, Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $78.75.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.